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High-technology in the Midwest—Biotech and beyond
by William A. Testa, vice president and senior economist
Industrial production long was the heartbeat of the Midwest economy. As that industry’s
role in the region diminishes, policymakers have explored new directions. At a series
of conferences, local experts discussed the potential of the biotech industry as the
Midwest’s next frontier.
Although the Midwest is home to signif-
icant research and development (R&D)
activity, this role has not led to an abun-
dance of start-up companies or rapid
growth of emerging technology indus-
tries. In 2005, the Economic Develop-
ment Council of Chicago (EDC), the
Federal Reserve Bank of Chicago, and
other local organiza-
tions sponsored a se-
ries of meetings to
analyze the potential
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itself if it is to sus-
tain its high standard of living and its
size and importance. No longer having
industrial production as its dominant
activity, Chicago is now a “learning
city,” a business meeting center for the
nation and the world, a corporate
headquarters for the mid-continent,
and a business services city that sells to
the broader Midwest region, to the na-
tion, and to global markets. But are
these economic strengths sufficient?
How might emerging technologies
and associated new firm creation con-
tribute to Chicago’s future?
For some cities, such as San Francisco,
Seattle, Boston, and Austin, TX, industry
sectors centered on emerging technol-
ogies have contributed significantly to
revitalizing the local economy. However,
in the Chicago area, these sectors—
measured by commercial activity rather
than R&D—are somewhat small relative
to Chicago’s economic size and R&D
performance. Especially in biomedical
science, Chicago’s degree of new firm
formation appears undersized, given the
significant R&D dollars flowing to the
region’s universities, hospitals, and
federal laboratories. If this spending
implies a significant potential for tech-
nology-driven growth in Chicago, what
types of efforts from the public and
private sectors might help bring about
its full development?
Experience from other regions indicates
that technology companies tend to multi-
ply and grow most rapidly in “economic
clusters.” Clusters are groups of like-
minded and highly interrelated firms
situated in proximity. Cluster firms’ prox-
imity, composition, and relationships
are conducive to creating new firms
and regenerating economic activity.
Once a high-tech cluster exists, it is some-
what resistant to competitive induce-
ments from other locations. That is partly
NOTE: Total funding from National Institutes of Health (NIH) to the Midwest was
$3.6 billion, representing 16% of the U.S. total.
SOURCE: National Institutes of Health.
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dollarsbecause both firms and workers with
specialized skills benefit from their
proximity. By working in the cluster,
the skilled worker gains a form of job
security from the myriad employment
opportunities at hand in the event of a
job change, as well as a strong chance
for career advancement at a number
of nearby firms. Some of these workers
go on to create new businesses of their
own. Firms in a cluster benefit from
the ability to hire skilled workers quickly
and at a reasonable cost when a growth
opportunity emerges. In addition, firms
often choose to locate in a cluster because
there are “ideas in the air.” Locating else-
where might mean missing out on an
emerging technology or key industry
direction. Of course, the presence of
key business service activities—especially
a venture capital community and spe-
cialized legal services—are also impor-
tant to firms.
What policies might support the devel-
opment of a cluster? And if public in-
vestment is made, how is success to be
measured?
Biotech landscape
Much of the March 22 conference dis-
cussion of Midwest performance and
strategy centered on the biopharma-
ceutical industry, an emerging growth
sector of small companies and innova-
tive products that has expanded steadily
in the U.S. in recent years. Although the
Midwest is home to a number of large
drug and medical device manufactur-
ers, including Eli Lilly and Co. (head-
quartered in Indianapolis), Abbott Labs
and Baxter (Chicago), and significant
Pfizer research/production facilities (in
Michigan), none of the nation’s most
prominent biotech companies is based
here. Still, policymakers are cautiously
optimistic about this sector because the
big pharmaceutical companies are in-
creasingly looking to biotech companies
as their pipeline to new and innovative
products. Nationally, this younger breed
of companies is only now coming to ma-
turity after decades of development: Over
the past two years, biotech firms have
brought more new drugs to market than
the earlier generation of pharmaceuticals.
Rising health care demand ensures that
the global industry (and private sector
financing of new companies) will remain
robust. The U.S. government funding for
basic R&D also has been growing strong-
ly. The National Institutes of Health
(NIH), the largest government funding
agency of its kind, has increased its re-
search funding by more than 2.5 times
since 1997, to more than $26 billion
for 2004.
Recent growth in the biopharmaceutical
industry, along with its strong growth
prospects, have made biotech firms cov-
eted development prizes for local and
state economies. Though still modest
in size—an estimated 407,000 workers
nationwide in 2003—the industry has
been gaining job share, especially since
the mid-1990s.2 Moreover, studies such as
those produced by the Milken Institute
claim that these companies spur growth
in other sectors of the local economy,
including retail, wholesale, and business
services. In addition, because they gen-
erally employ highly skilled workers,
biopharmaceutical companies often pay
more than those in other sectors.
So far in the Midwest, proximity to big
pharmaceuticals has not been sufficient
motivation to give rise to a crop of start-
up companies or research alliances. A
study by Joe Cortright of Impressa iden-
tified nine national centers of biotech
activity—Boston; the San Francisco
Bay Area; San Diego; Washington, DC;
Raleigh–Durham, NC; Austin, TX; Seattle;
Los Angeles; and Philadelphia.3 These
nine centers dominated 51 large U.S.
metropolitan area in the following cri-
teria: NIH funding, patents filed, venture
capital, R&D alliances, new firms, and
large firms. The nine centers averaged
over $800 million in NIH research fund-
ing in 2000, versus an average of $104
million for the remaining 42 metro areas
(among them, Chicago), with ten times
as many biotech-related patents filed and
35 times as much venture capital going
to biotech companies. Clearly, biotech
industry activity is marked by a high
degree of spatial clustering.
Cortright further argued that the cluster-
ing tendency has been sharpening rather
than diminishing in recent years in terms
of venture capital, new firms, and allianc-
es. Accordingly, many of the regions that
are now chasing a share of the existing
or future biotech are doomed to fail.
Their efforts are “expensive, risky, and
time-consuming.” A prominent example
is Florida’s recent public subsidy pack-
age, reportedly worth between $700
million and $800 million to The Scripps
Research Institute, to locate a research
facility in the Palm Beach area.
Are all regions aside from the top nine
destined to fail? One conference partic-
ipant cited the San Diego area as a late
entrant into the group of nine, so it may
be quite logical for other regions with
complementary characteristics to en-
courage biotech development. However,
to be successful, those regions need to
understand and possess many of the
elements that are conducive to the de-
velopment of industry clusters. One nec-
essary condition for a thriving biotech
industry is a strong local research base.
Most of the nine biotech centers feature
a strong academic R&D base in the bio-
sciences, although Philadelphia and Los
Angeles do not stand out in this regard.
However, it is also true that a strong
R&D base is not sufficient in itself to
give rise to the development of new
firms. Indeed, Cortright’s study identi-
fies four U.S. metro areas as scoring
very high as “research centers,” but
lacking in commercial biotech activity.
These four metro areas are St. Louis,
Detroit, Chicago, and Houston.
Given this strong base, why aren’t mid-
western states performing better in
commercialization of research into new
firms and alliances? Speaking at the
Chicago Fed on April 26, 2005, Dan
Broderick, principal at Mason-Wells Co.,
a Milwaukee-based venture capital firm,
suggested that, taken as a whole, research
activity in Midwest states is prodigious.
For example, NIH funding in the
Midwest equaled $3.2 billion in 2003,
which is 17% of the U.S. total (figure 1).
However, this activity may be too geo-
graphically dispersed to easily generate
the interactions among firms and with
potential investors that ultimately lead to
clusters. Accordingly, he argued, Midwest
states should focus on policies that tie
their activities together and otherwise
encourage maximum effectiveness of
existing biotech industry associations
and government incentive programs.
One important arena is venture capital
flow, a measure in which the Midwest
lags national benchmarks. Broderick
suggested that greater cooperation or
even consolidation among state venture
capital associations would enable venture
capitalists to review potential deals more
quickly, thereby boosting Midwest inroads
into the biopharmaceutical arena. As a
private sector initiative toward the same
end, Broderick directs the Mid-America
Healthcare Investors Network (MHIN),
a recently formed association of over
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New U.S. U.S. Options and License New
New patents patents licenses revenue start-ups
State disclosures filed issued executed ($000s) licensed
Illinois 570 310 183 124 15,399 9
Indiana 267 188 53 99 5,219 7
Iowa 209 94 53 231 14,473 2
Michigan 378 190 112 109 45,566 11
Minnesota 444 130 123 189 47,983 4
Missouri 150 95 63 43 15,476 3
Ohio 435 90 71 96 14,805 9
Wisconsin 446 165 90 184 38,318 2
Total 2,899 1,262 748 1,075 197,239 47
2. Technology indicators at Midwest university research consortium members
promote deal syndication and health care
investing opportunities in the Midwest.
Universities are often a major source of
technology that can be commercialized.
But the Midwest’s flagship research
universities are notably dispersed, not
only from each other, but also in many
cases from the major commercial cit-
ies in their home states—for example,
the major research centers of the state
university systems of Illinois, Indiana, and
Wisconsin, respectively, are in Urbana–
Champaign, Purdue, and Madison—not
Chicago, Indianapolis, and Milwaukee.
Locating university research centers in
commercial hubs would facilitate com-
panies’ and venture capitalists’ search
for and review of technologies. Alter-
natively, Midwest universities might be
more effective through cooperative ac-
tivities and ventures.
Among key Midwest research universi-
ties, such cooperative efforts have al-
ready begun. At the May 19 conference,
David Gulley, assistant vice chancellor
for research at the University of Illinois,
described the efforts of the Midwest
Research University Network (MRUN).
MRUN was established in 2002 as an
alliance of university business develop-
ment professionals to facilitate technolo-
gy development, notably through start-up
formation. Eighteen MRUN member
institutions exchange information about
financing, placement of management
talent, and opportunities for collabora-
tion. In all activities, not just bioscience,
MRUN member organizations licensed
47 start-up companies in 2003 and ac-
crued $197 million in revenues from
licensing agreements (figure 2).
The Midwest can also learn from the ex-
periences of other places in the U.S. and
around the world. At the April 26 con-
ference, Susan M. Walcott, professor of
geography at Georgia State University,
offered her perspectives on biotech clus-
ter regions around Indianapolis, San
Diego, Atlanta, and the research triangle
in North Carolina, along with emerging
centers in China and India. Walcott add-
ed several important conditions for suc-
cessful commercialization of technology
and research: a culture of encouraging
effort and of trying again after failures,
active local institutions for information
exchange, a high quality of life to attract
and retain knowledge workers, and a spe-
cialized business infrastructure such as
programs to develop university research.
In addition, networking among local bio-
scientists and interested businesspeople
can be critical. Often, a leading individ-
ual, corporation, or organization can be
instrumental in promoting local biotech
growth. For example, Indianapolis bene-
fited from the commitment of Eli Lilly
and Co., whose involvement supported
a closely networked set of facilities, sup-
pliers, university partnerships, and ulti-
mately start-ups. In San Diego, networking
efforts such as CONNECT (an early stage
venture and seed capital network) and
BIOCOM (the overall biotech commu-
nity association) have encouraged joint
ventures and start-ups alike.
Undoubtedly, the weather in San Diego
has also helped the area to retain grad-
uates of the University of San Diego,
recruit star scientists, and encourage
entrepreneurs to start new businesses.
Many of these new business owners left
existing local companies and chose to
stay in San Diego. The lesson for the
Midwest is that mentoring by the region’s
successful company leaders is to be en-
couraged, along with efforts to enhance
the quality of life and the development
of local amenities.
While the U.S. continues to dominate
biotech activity around the globe, many
new clusters have developed overseas—for
example, in Suzhou–Shanghai (China),
Stockholm, Singapore, Hyderabad
(India), Munich, and Jerusalem. The
public and public–private efforts that
have supported the growth of these clus-
ters largely reflect local conditions,
government structure, and culture.
Developing technology centers
At the May 19 meeting, Diane Palmintera,
founder and president of Innovation
Associates, Inc., discussed the specific
actions and programs that regions can
pursue in growing technology sectors.
It is not sufficient for universities to
provide the research base upon which
clusters are built; they must also make a
commitment to pursuing commercializa-
tion opportunities and provide rewards
and incentives for those who succeed in
transferring their research to the busi-
ness sector. In this regard, the University
of Wisconsin–Madison is a notable
regional leader, having launched four
start-up companies in 2003. National
leaders MIT and Stanford launched 17
companies each that same year. Well-
funded research activities are a huge start-
ing point for any commercialization
success. In this, private companies and
industries represent an important source
SOURCE: Midwest Research University Network.of funding to supplement that provid-
ed by government. Private support is
particularly important to the develop-
ment phase of commercial technology,
such as licensing and very early stage
product development. Successful uni-
versities often facilitate access to seed
capital and also provide management
services to their scientist-entrepreneurs.
Mentoring of fledgling companies by
successful scientist-entrepreneurs is also
often helpful in university programs.
How do cities and states leverage univer-
sity resources? Coordinated strategic ef-
forts can be aimed at increasing federal
and state funding and building university-
centered initiatives. These include en-
listing private industry and foundations
to help promote and fund science and
technology initiatives, encouraging the
development of seed capital and investor
networks, and seeking CEOs who have
been successful in building businesses to
mentor or champion new firm formation
in the region. Funding “innovation cen-
ters” can also combine multiple com-
ponents of needed resources so as to
provide a central focus for university-
based community activities. Such com-
ponents are collaborative R&D, tech
“scouting,” seed capital, mentoring, and,
most importantly, networking among
the many interests.
Beyond biotech
Biotech is perhaps foremost on the minds
of Midwest economic development lead-
ers these days, not only because the in-
dustry is growing and maturing, but
because the nation’s leading biotech
conference, BIO2006, will be held in
Chicago, which will highlight the entire
Midwest’s biotech technological and
economic base. However, biotech is but
one of several promising technologies
that could either create new industries
here or revive the existing economic base.
For example, Midwest policymakers are
also excited about nanotechnology, which
is “the creation and utilization of mate-
rials, devices, and systems through the
control of matter at length scales less
than 100 nanometers.” According to
Nik Rokop, president of the Chicago
Microtechnology & Nanotechnology
Community, who spoke on May 19, the
Midwest is unsurpassed in its nano-sci-
entific base, having published more sci-
entific papers in this field than any other
U.S. region. On the commercial side,
new materials being developed through
nano-scientific methods are expected to
help keep the region’s manufacturers
competitive through new or better ma-
terials in production and new products.
And while the whole nanotech area is rel-
atively new, many start-ups in the Midwest
are already generating revenues.
Importantly, technological areas are in-
creasingly overlapping or “converging,”
and interdisciplinary initiatives are com-
mon in achieving breakthrough results.
For example, biotech tools are increas-
ingly being applied outside of human
health, such as in agriculture (e.g., geneti-
cally modified crops) and in industrial
applications, such as ethanol and other
biofuels. So too, advanced computational
tools have spawned the research area of
“infomatics” in biological applications,
whereby research avenues to drug and
material discovery are being sought with
computational tools rather than lab
experimentation alone. Nano-scale re-
search applications to human health, in-
cluding diagnostics and drug delivery,
are an increasingly important part of
human health research. In view of these
intersections, policymakers in some
metro areas are beginning to develop
broader tech promotion and support
strategies. Minneapolis–St. Paul is al-
ready noted for its broadly diversified
and cross-disciplinary success.
Conclusion
Participants in the EDC meetings were
asked to volunteer to staff smaller task
forces during the summer of 2005 to fur-
ther explore more specific technology
and policy directions and to make recom-
mendations to policymakers and indus-
try associations throughout the Midwest.
Their reports will help guide policymak-
ers as they seek to increase the level of
development and commercialization of
the Midwest’s significant research activity.
1 Conferences were organized under the
umbrella of the Economic Development
Council of Chicago and co-sponsored by
the Chicago Fed and other organizations.
Meeting agendas and individual presen-
tations can be found at the council’s
website, www.edcchicago.com.
2 See Milken Institute, 2004, Biopharmaceu-
tical Industry Contribution to State and U.S.
Economies, October.
3 See Joe Cortright and Heike Mayer, 2002,
Signs of Life: Clustering of Biotechnology in
U.S. Metropolitan Areas, Impressa.